DOCSLIB.ORG

Simeprevir, Faldaprevir and Sofosbuvir

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2nd wave IFN-based triple therapy for HCV genotype 1: Simeprevir, Faldaprevir and Sofosbuvir. Paris Hepatitis Conference Pr Tarik Asselah 14 janvier 2014 MD, PhD Service d’Hépatologie & INSERM U773 University Paris Diderot Hôpital Beaujon, Clichy [email protected] 2nd wave IFN-based triple therapy for HCV genotype 1: Simeprevir, Faldaprevir and Sofosbuvir. • Introduction • New IFN-based triple therapy for HCV genotype 1 Protease inhibitors - Simeprevir (Quest-2, Promise) - Faldaprevir (StartVerso 1, StartVerso 3) - Other PI : MK5172, Asunaprevir, etc…. Polymerase inhibitor - Sofosbuvir (Neutrino) • Summary and Conclusion Direct-acting antivirals 5’NTR Structural proteins Nonstructural proteins 3’NTR Metalloprotease Envelope Serine protease Glycoproteins RNA Capsid RNA helicase Cofactors Polymerase C E1 E2 NS1 NS2 NS3 NS4A NS4B NS5A NS5B Protease Inhibitors NS5A Inhibitors Polymerase Inhibitors Telaprevir Daclatasvir Nucs Non-Nucs Boceprevir Ledipasvir Simeprevir ABT-267 Sofosbuvir ABT-333 Faldaprevir GS-5816 VX-135 Deleobuvir Asunaprevir ACH-3102 IDX-20963 BMS- ABT-450 PPI-668 791325 MK-5172 GSK-2336805 ACH-3422 PPI-383 Sovaprevir Samatasvir GS-9669 ACH-2684 MK-8742 TMC-647055 Schinazi R, Halfon P, Marcellin P, Asselah T. Liver International 2014 Investigational HCV Regimens in Phase III Trials in 2014 Triple Therapy: 1 DAA + PegIFN alfa/RBV IFN-Free Regimens . Simeprevir (PI) . Sofosbuvir + RBV . Faldaprevir (PI) . Sofosbuvir + GS-5885 (FDC) ± RBV . Sofosbuvir (NI) . Daclatasvir + asunaprevir . Daclatasvir (NS5A) . ABT-450/RTV + ABT-267 ± ABT-333 ± RBV . MK 5172 (PI) . Faldaprevir + BI207127 + RBV . Danoprevir (PI) . MK 5172 + MK 8742 . Alisporivir (CYP) Asselah and Marcellin P,. Liver International 2014 General Characteristics of Direct-Acting Antivirals NS5A NS5A NS5B NS5B Non PI, 1st PI, 2nd Inhibitors, 1st Inhibitors, 2nd Nucleoside Nucleoside Generation Generation Generation Generation Inhibitors Inhibitors Efficacy Resistance Profile Pangenotypic Efficacy Adverse events Drug-drug interactions Good profile Average profile Least favorable profile Schinazi R, Halfon P, Marcellin P, Asselah T. Liver International 2013 Priorities for Direct-Acting Antivirals Potency Genotype Coverage Highest Importance Resistance Barrier Safety/Tolerability Treatment Duration Half life & Pills burden Drug-drug Interaction Secondary Priorities Cost Schinazi R, Halfon P, Marcellin P, Asselah T. Liver International 2013 2nd wave IFN-based triple therapy for HCV genotype 1: Simeprevir, Faldaprevir and Sofosbuvir. • Introduction • New IFN-based triple therapy for HCV genotype 1 Protease inhibitors - Simeprevir (Quest-2, Promise) - Faldaprevir (StartVerso 1, StartVerso 3) - Other PI : MK5172, Asunaprevir, etc…. Polymerase inhibitor - Sofosbuvir (Neutrino) • Summary and Conclusion Simeprevir (SMV) (PI): G1, phase III trial design Response-guided treatment QUEST-1, naïve n=264 PR SMV 150mg + PR Follow-up PR Follow-up n=130 Placebo + PR PR Placebo + PR Follow-up 0 12 24 48 72 QUEST-2, naïve SMV 150mg + PR N=257 PR Follow-up PR Follow-up N=134 Placebo + PR PR PR Follow-up Week 0 12 24 48 72 PROMISE, relapsers SMV 150 mg PR N=260 PR Follow-up + PR Follow-up N=133 PBO + PR PR PR Follow-up Week 0 12 24 48 72 9 Simeprevir (SMV) SVR12 (%) Proportion of patients, % *Based on the Cochran-Mantel-Haensze test controlling for type of PegIFN/ribavirin and stratification factors Placebo/PR 67/134 50 (PI): G1 naïve, phase III (QUEST-2) (PI): G1 naïve, phase III (QUEST-2) P <0.001* Manns et al. EASL 2013, Abstract 1413. Abstract 2013, EASL al. Manns et 209/257 SMV/PR 81,3 QUEST-2: Response-guided Treatment (RGT) allows shortened treatment duration with high SVR12 SVR12 in SMV/PR 100 86 80 s 91.4% (235/257) t n e of patients met ti a 60 p RGT criteria and f o n were eligible for o ti r 40 24 weeks of o p o treatment r P 20 202/235 0 202/235 • 8.6% (22/257) of patients did not meet RGT criteria – among them, 31.8% (7/22) achieved SVR12 RGT, response-guided therapy; RGT criteria: HCV RNA < 25 IU/mL detectable or undetectable at Week 4 and <25 IU/mL undetectable at Week 12 10 Quest-2: Changes in haemoglobin Hemoglobin Entire treatment phase – hemoglobin, µmol/L 200 Placebo 180 E SMV S ± , 160 s e u l a 140 v n a e 120 M 100 0 2 4 8 12 16 20 24 36 48 Weeks Manns et al. EASL 2013, Abstract05.03.2013 1413. 11 Simeprevir (SMV) (PI): G1 relapsers (Promise) SMV/PR Placebo/PR SVR12 (%) 100 84 85 75 80 58 52 53 60 47 43 40 20 62/131 191/254 23/44 49/84 36/83 138/165 70/133 228/267 0 G1a G1a G1a G1b with Q80K without Q80K Lawitz et al. DDW 2013, Abstract 869b. Simeprevir: adverse events (phase III trials) QUEST-1 QUEST-2 PROMISE Placebo + PR, Placebo + PR, SMV + PR, % Placebo + PR, % SMV + PR, % SMV + PR, % % % (N = 264) (N = 134) (N = 257) (N = 264) (N = 130) (N = 130) Serious AEs 4 3 2 2 4 3 Discontinuation 3 3 1 2 3 3 due to AEs Fatigue 38 40 39 35 Pruritus 11 21 15 19 28 28 Rash (any type) 25 27 11 24 23 23 Anaemia 11 16 14 16 20 17 Jacobson et al. DDW 2013, Abstract 1674582. Manns et al. EASL 2013, Abstract 1413. Lawitz et al. DDW 2013, Abstract 869b. Simeprevir (PI): 12 weeks phase III trial (G1 naïve) Ongoing trial Response-guided therapy of 12 or 24 weeks guided by HCV-RNA measurements at treatment weeks 2, 4, and 8. Baseline Week 4 Week 12 Week 24 Week 36 Week 48 Follow up N=150 patients. Single arm, open-label Triple Therapy SMV + PR Continue PR to Wk 24 Follow up PR: PegIFNα-2a 180 ug/wk + RBV 1000-1200mg/day Clinicaltrials.gov: NCT01846832 Faldaprevir (FDV) (PI): phase III trial, G1 naïve (StartVerso1) Arm 1 Placebo + PR PR Follow-up (n=133) ETS Placebo + PR Follow-up Arm 2 FDV 120 mg + (n=261) PR No ETS FDV 120 mg + PR PR Follow-up ETS Follow-up Arm 3 FDV 240 mg + Placebo + PR (n=262) PR No ETS PR Follow-up Day 1 Week 12 Week 24 Week 48 Week 72 Ferenci et al. EASL 2013, abstract LB 1416. Faldaprevir (FDV) (PI): G1 naïve, results (StartVerso1) (∆ = 26.7; 95% CI, 17.1–36.3; p<0.0001) (∆ = 28.6; 95% CI, 19.0–38.2; p<0.0001) ) % ( 2 1 R V S 69/132 204/259 210/261 SVR12 rates adjusted for race and genotype ITT, intention-to treat shortened treatment duration with high SVR12 Faldaprevir (FDV) and <25 IU/mL (undetected) at Week 8. aDenominator 8. patientswithETS = Week (undetected) at and<25IU/mL 4 Week undetected) orat (detected <25IU/mL HCVsuccess: RNA early treatment ETS, Proportion of patients (%) : Early treatment success (ETS) allows(ETS) success : Early treatment FDV 120 mg ETS 226/259 ETS ETS + SVR12a FDV 120 mg 194/226 Changes in haemoglobin Mean haemoglobin ± SD (g/dL) 16 10 14 12 18 8 0 4 8 Weeks 12 16 FDV 120 mg + PR PR + mg 120 FDV Placebo + PRPlacebo + FDV 240 mg + PR + mg 240 FDV 20 24 Faldaprevir: adverse events (phase III trial results) Placebo + PR FDV 120 mg + PR FDV 240 mg + PR N=264 N=521 N=524 AEs leading to discontinuation of all 10 (4) 27 (5) 40 (8) medication, n (%) AEs leading to discontinuation of FDV 1 (<1) 6 (1) 14 (3) or placebo only, n (%) Serious AEs, n (%) 16 (6) 39 (7) 43 (8) AEs of at least moderate intensity 156 (59) 302 (58) 332 (63) (any)a, n (%) Rash 11 (4) 39 (7) 50 (10) Photosensitivity 0 (0) 0 (0) 3 (1) GI 19 (7) 58 (11) 96 (18) Anemia 38 (14) 73 (14) 70 (13) Bilirubin associated 2 (1) 18 (3) 47 (9) One patient with cirrhosis at baseline developed acute-on-chronic liver failure after 16 days of FDV (24 0mg) and PR, discontinued all treatment and died 12 days later. The event was considered not related to FDV but to pegylated interferon by investigator. aDAIDS Grade 2 to 4; protocol-defined AEs of special interest. DAIDS, Division of AIDS table for grading the severity of adult and pediatric adverse events; DC, discontinuation; GI, gastrointestinal. Faldaprevir (PI): phase III trial design, G1 experienced (StartVerso3) Prior relapse Relapser: Rebound from HCV Arm 1 (n=49) Placebo + PR PR RNA undetectable at end of 48 week treatmenta but Arm 2 (n=99) FDV 240 mg + PR Placebo + PR PR (RGT a) detectable within 24 weeks of follow-up Arm 3 (n=102) FDV 240 mg + PR PR (RGT a) Prior partial response Partial responder: HCV RNA Placebo + PR PR drop by ≥2 log10 from baseline Arm 1 (n=29) to week 12, but never FDV 240 mg undetectable Arm 2 (n=57) + PR Placebo + PR PR Breakthrough: HCV RNA undetectable during treatment, Arm 3 (n=55) FDV 240 mg + PR PR but rebound to detected during ongoing treatment Prior null response Arm 1 (n=146)b FDV 240 mg + PR Placebo + PR PR Null responder: Absence of HCV RNA drop by ≥2 log10 Arm 2 (n=141) FDV 240 mg + PR from baseline to week 12 PR Day 1 Week 12 Week 24 Week 48 aStopping rule for RGT criteria: all relapsers, who did not achieve ETS (HCV RNA <25 IU/mL (detected or undetected) at week 4 and <25 IU/mL (undetected) at week 8, had extended PR treatment to week 48; bN=146 patients randomized, but N=145 patients treated. PR, pegylated interferon α-2a/ribavirin; QD, once daily; RGT, response-guided therapy. Jacobson et al. AASLD 2013, abstract 1100. Faldaprevir (FDV) (PI): SVR12, G1 experienced (StartVerso3) 100 Prior relapse Prior partial response 80 70 70 60 58 Prior null response 47 40 33 33 20 14 3 7/49 69/99 71/102 1/29 33/57 26/5526/55 48/145 46/14146/141 0 FDV FDV FDV FDV FDV FDV Placebo Placebo 12 weeks 24 weeks 12 weeks 24 weeks 12 weeks 24 weeks MK-5172 (PI) plus PEG-IFN/RBV: G1 naïve non-cirrhotic SVR24 and HCV-RNA TND at Last Visit* 99 % 96 % 98 % 92 % (67/68) (64/67) (64/65) 100 (61/66) ) % ( t 67 % i s i 75 (44/66) v t s a l t a 50 D 86 % 92 % 91 % 87 % N T (55/64) (61/66) (58/64) (52/60) r o 25 54 % 4 2 (31/57) R V S 0 BOC + PR MK-5172 MK-5172 MK-5172 MK-5172 100 mg + PR 200 mg + PR 400 mg + PR 800 mg + PR SVR24 HCV RNA TND at last visit Manns et al.
Recommended publications
  • Faldaprevir, Pegylated Interferon, and Ribavirin for Treatment-Naïve HCV Genotype-1: Pooled Analysis of Two Phase 3 Trials

    Faldaprevir, Pegylated Interferon, and Ribavirin for Treatment-Naïve HCV Genotype-1: Pooled Analysis of Two Phase 3 Trials

    Faldaprevir, pegylated interferon and ribavirin. , 2016; 15 (3): 333-349 333 ORIGINAL ARTICLE May-June, Vol. 15 No. 3, 2016: 333-349 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association for the Study of the Liver Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials Donald M. Jensen,1 Tarik Asselah,2 Douglas Dieterich,3 Graham R. Foster,4 Mark S. Sulkowski,5 Stefan Zeuzem,6 Parvez Mantry,7 Eric M. Yoshida,8 Christophe Moreno,9 Denis Ouzan,10 Mark Wright,11 Luis E. Morano,12 Robert Buynak,13 Marc Bourlière,14 Tarek Hassanein,15 Shuhei Nishiguchi,16 Jia-Horng Kao,17 Masao Omata,18 Seung W. Paik,19 David K. Wong,20 Edward Tam,21 Kelly Kaita,22 S. Victor Feinman,23 Jerry O. Stern,24 Joseph Scherer,24 Anne-Marie Quinson,24 Florian Voss,25 John-Paul Gallivan,25 Wulf O. Böcher,25 Peter Ferenci26 1 University of Chicago Medicine, Chicago, IL, USA. 2 Hôpital Beaujon, APHP, University Paris-Diderot and INSERM CRB3, Clichy, France. 3 Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4 Queen Mary University of London, London, UK. 5 Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6 J.W.Goethe University Hospital, Frankfurt, Germany. 7 The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA. 8 University of British Columbia, Vancouver, BC, Canada. 9 CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 10 Institut Arnault Tzanck, St.
  • Faldaprevir Combined with Peginterferon Alfa2a and Ribavirin In

    Faldaprevir Combined with Peginterferon Alfa2a and Ribavirin In

    Faldaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Virus Genotype-1 Patients With Prior Nonresponse: SILEN-C2 Trial Mark S. Sulkowski,1 Marc Bourlie`re,2 Jean-Pierre Bronowicki,3 Tarik Asselah,4 Jean-Michel Pawlotsky,5 Stephen D. Shafran,6 Stanislas Pol,7 Stefan Mauss,8 Dominique Larrey,9 Yakov Datsenko,10 Jerry O. Stern,11 George Kukolj,12 Joseph Scherer,11 Gerhard Nehmiz,10 Gerhard G. Steinmann,10 and Wulf O. B€ocher13 Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor. In all, 290 noncirrhotic HCV genotype (GT)-1 patients with prior null (<1log10 viral load [VL] drop at any time on treatment) or partial response (1log10 VL drop but never undetectable on treatment) were randomized 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in combination with faldaprevir 240 mg once daily (QD) with 3 days PegIFN/RBV lead-in (LI), 240 mg QD without LI, or 240 mg twice daily (BID) with LI. Patients in the 240 mg QD/LI group achieving maintained rapid virologic response (mRVR; VL <25 IU/mL [Roche TaqMan] at week 4 and undetectable at weeks 8 to 20) were rerandomized to cease all treatment at week 24 or continue PegIFN/RBV up to week 48. Sustained virologic response (SVR) rates were 32%, 50%, and 42% in prior partial responders, and 21%, 35%, and 29% in prior null responders in the faldaprevir 240 mg QD/LI, 240 mg QD, and 240 mg BID/LI groups, respectively.
  • UNO Template

    UNO Template

    26 November 2013 Americas/United States Equity Research Biotechnology Global Biotech & Pharma: The HCV Revolution - Edition 2 Research Analysts COMMENT Ravi Mehrotra PhD 212 325 3487 [email protected] What Is The N Number: Keeping An Eye On Vamil Divan, MD 212 538 5394 Potential Longer Term Pricing Disruption [email protected] Koon Ching PhD ■ No pricing disruption expected in the near-term, but potential exists in 212 325 6286 the medium- to long-term. OK this is somewhat obvious, but bear with us: [email protected] Value/NPV = Price x Mkt Share x Mkt Size x Mkt Longevity. This is the Bruce Nudell PhD second note in our "The HCV Revolution" series. HCV is clearly a highly 212 325 9122 competitive therapeutic area with many players vying for their share of the [email protected] potentially >$15B/year HCV market. We previously addressed immediate- European Pharma Team 44 207 888 0304 term pricing of next-generation regimens, specifically for Sofosbuvir (LINK). [email protected] In this note, we simply highlight the potential number of competing all-oral, Ronak H. Shah, Pharm.D., CFA IFN-free regimens, and timing of key data, in HCV (Exhibits 1-7). The 212 325 9799 number of ultimate competitors has important implications for the HCV [email protected] market. In our view, in a HCV market with up to 4−5 players, we expect Lee Kalowski "normal drug rules" to apply: i.e. the order to market, overall clinical profile of 212 325 9683 drug, and commercial prowess will primarily dictate market share, with price [email protected] used as a tool but not in a "disruptive" way.
  • Startverso4 PHASE III TRIAL of FALDAPREVIR PLUS PEGYLATED INTERFERON Α-2A and RIBAVIRIN in PATIENTS with HIV and HCV GENOTYPE-1 CO-INFECTION

    Startverso4 PHASE III TRIAL of FALDAPREVIR PLUS PEGYLATED INTERFERON Α-2A and RIBAVIRIN in PATIENTS with HIV and HCV GENOTYPE-1 CO-INFECTION

    STARTVerso4 PHASE III TRIAL OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN PATIENTS WITH HIV AND HCV GENOTYPE-1 CO-INFECTION JK Rockstroh1, M Nelson2, V Soriano3, K Arastéh4, J Guardiola5, S Bhagani6, J Mallolas7, C Tural8, M Puoti9, P Ingiliz10, M Battegay11, MK Jain12, M Núñez13, K Marks14, J Kort15, JO Stern15, R Vinisko15, M Manero16, D Dieterich17, on behalf of the STARTVerso4 Study Group 1University of Bonn, Bonn, Germany; 2Chelsea and Westminster Hospital, London, UK; 3Hospital Carlos III, Madrid, Spain; 4EPIMED, Vivantes Auguste-Viktoria Hospital, Berlin, Germany; 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6Royal Free Hospital, London, UK; 7Hospital Clínic, Barcelona, Spain; Jürgen K. Rockstroh 1099 8Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 9AO Ospedale Niguarda Cà Granda, Milan, Italy; 10Medizinisches Infektiologiezentrum Berlin (MIB), Berlin, Germany; 11Division of Infectious Diseases and Hospital Epidemiology, Basel, Switzerland; 12UT Southwestern Medical Center, Dallas, TX, USA; 13Wake Forest University, Winston-Salem, NC, USA; 14Weill Cornell Medical College, New York, NY, USA; 15Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 16Boehringer Ingelheim España S.A., Barcelona, Spain; 17Mount Sinai School of Medicine, New York, NY, USA [email protected] BACKGROUND RESULTS EFFICACY FIGURE 4e. SVR4 by ART (total population) TABLE 5. AE summary ●● SVR4 was achieved by 74% of patients overall (Figure 3). FDV 120 mg FDV 240 mg + PR + PR Total ●● Faldaprevir (FDV) is a potent inhibitor of HCV NS3/4A.1 PATIENTS - SVR4 rates were comparable across FDV doses and durations of treatment. 24 weeks Total FDV + PR a ●● 1 n (%) (N=123) (N=185) (N=308) FDV has antiviral activity against HCV genotypes (GT) 1, 4, 5, and 6 in vitro.
  • Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors

    Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors

    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 197 Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors Targeting Different Genotypes and Drug-Resistant Variants ANNA KARIN BELFRAGE ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6192 ISBN 978-91-554-9166-6 UPPSALA urn:nbn:se:uu:diva-243317 2015 Dissertation presented at Uppsala University to be publicly examined in B41 BMC, Husargatan 3, Uppsala, Friday, 27 March 2015 at 09:15 for the degree of Doctor of Philosophy (Faculty of Pharmacy). The examination will be conducted in Swedish. Faculty examiner: Ulf Ellervik (Lunds tekniska högskola). Abstract Belfrage, A. K. 2015. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors. Targeting Different Genotypes and Drug-Resistant Variants. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 197. 108 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9166-6. Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. The chemical foundation of the approved and late-stage HCV NS3 protease inhibitors is markedly similar. This could partly explain the cross-resistance that have emerged under the pressure of NS3 protease inhibitors. The first-generation NS3 protease inhibitors were developed to efficiently inhibit genotype 1 of the virus and were less potent against other genotypes. The main focus in this thesis was to design and synthesize a new class of 2(1H)-pyrazinone based HCV NS3 protease inhibitors, structurally dissimilar to the inhibitors evaluated in clinical trials or approved, potentially with a unique resistance profile and with a broad genotypic coverage.
  • Incidence and Predictors of Hepatocellular Carcinoma In

    Incidence and Predictors of Hepatocellular Carcinoma In

    Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Milan, Italy The revolving alphabet soup of hepatitis viral infections Hepatitis C drug therapy – present© by and author future ESCMID Online Lecture Library Hepatitis C drug therapy • The present • The future © by author ESCMID Online Lecture Library Anti HCV agents Interferon and Ribavirin © by author ESCMID Online Lecture Library Viral Load vs. Time 1.E+08 • Lack of sensitivity to IFN 1.E+07 • Insufficient antiviral activity 1st phase 1.E+06 2nd phase • Defective clearance of DNA (cp/ml) DNA - 1.E+05 3rd phase infected cells HBV 1.E+04 4th phase 1.E+03 -7 7 21 35 ©49 by63 author77 91 105 119 133 147 161 175 Time (days) • In theESCMID first 2-3 weeks of therapy, Online the viral load Lecturedecline derives mainly Library from the reduction of viral production direct antiviral effect of the drug • Thereafter the viremia decline derives mainly from the clearance of infected cell Colombatto P et al.. Antiv Ther, 2003 Patterns of Virologic Response 7 Null response [1] 6 5 IU/mL) 10 4 Partial response 3 Relapse 40% chance 2 of SVR with © by author pegIFN/RBV[2] HCV RNA (log HCV RNA 1 Undetectable RVR EVR EOT SVR 0 ESCMID-8 -4 -2 0 4Online 8 12 16 Lecture20 24 32 40 48Library 52 60 72 Wks After Start of Therapy 1. Ghany MG, et al. Hepatology. 2009;49:1335-1374. 2. McHutchison JG, et al. N Engl J Med. 2009;361:580-593. WHAT WE HAVE LEARNED ABOUT TREATMENT (IFN) FAILURE Response to IFN alfa depends on : .
  • HCV Eradication with Direct Acting Antivirals (Daas)?

    HCV Eradication with Direct Acting Antivirals (Daas)?

    HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d’Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. [email protected] HCV eradication with direct acting antivirals (DAAs)? HCV replication HCV genome and DAAs targets NS3 inhibitors NS5A inhibitors NS5B inhibitors Take home messages HCV viral cycle Asselah et al. Liver Int. 2015;35 S1:56-64. Direct acting antivirals 5’NTR Structural proteins Nonstructural proteins 3’NTR Metalloprotease Envelope Serine protease Glycoproteins RNA Capsid RNA helicase Cofactors Polymerase C E1 E2 NS1 NS2 NS3 NS4A NS4B NS5A NS5B Protease Inhibitors NS5A Inhibitors Polymerase Inhibitors Telaprevir Daclatasvir Nucs Non-Nucs Boceprevir Ledipasvir Simeprevir ABT-267 Sofosbuvir ABT-333 Faldaprevir GS-5816 VX-135 Deleobuvir Asunaprevir Direct Acting Antivirals: 2015 Asselah et al. Liver Int. 2015;35 S1:56-64. Genetic barrier for HCV direct acting antivirals High Nucleos(t)ide 1 mutation= high cost to Analog Inhibitors fitness, 2-3 additional mutations to increase fitness 2 st generation Protease Inhibitors n Non Nucleos(t)ide Analog Inhibitors : NS5 A Inhibitors 1 st generation Protease Inhibitors 1 mutation= low cost to fitness Low Halfon et al. J Hepatol 2011. Vol 55(1):192-206. HCV protease inhibitors (PI) Inhibit NS3/NS4A serine protease responsible for the processing of the polyprotein 1st generation 1st generation, 2nd wave 2nd generation Resistance low low high barrier Genotype activity 1: 1 a< 1b All except 3 all Drug drug Important Less Less interaction Drugs Boceprevir Simeprevir (Janssen) MK-5172 Telaprevir Faldaprevir (BI) ACH-2684 Paritaprevir (ABT-450)/r (AbbVie) Vedroprevir (Gilead) Vaniprevir (Merck) Sovaprevir (Achillion) Asunaprevir (BMS) NS3/NS4A structure Repositioning of helicase domain Self cleavage Lipid Bilayer Inactive Insertion of the Active carboxy-terminal tail Bartenschlager et al.
  • Diapositiva 1

    Diapositiva 1

    Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic, Higher SVR, Eventually Oral for all patients SVR: 70-80% ≥ 90% ≥ 90% 2013 2014 2015 Genotype 2&3 Genotype 2 Genotypes 1-6 P/R SOF+RBV 12 weeks SOF+LPV ± RBV Genotypes 1 Genotype 3 ABT-450+ABT-267+ Telaprevir + P/R SOF+RBV 24 weeks ABT- 333 +RBV Boceprevir + P/R Genotypes 1-4 DCV+ASU SOF+ P/R SOF+DCV Genotypes 1&4 SMV+ P/R HCV Resistance to DAA During DAA-based treatment: ■ Rapid selection of resistance mutation may occur, eventually leading to viral break-through. Kieffer et al. Hepatology 2007; 46:631-9 Pilot-Matias et al. 46th EASL 2011, Abs1107 ■ Several changes at different positions at the NS3 protease, NS5B polymerase, and NS5A protein have been associated with loss of susceptibility to DAAs. Sarrazin et al. Gastroenterology 2010;138:447-62 MainTable 2. Main characteristics characteristics of the genotype of theactivity genotypeand resistance of DAA activity classes. and resistance of DAA classes. Genotype activity Resistance Key resistance mutations NS3 ■ First PI generation: genotypes 1 (1b >1a) Low genetic barrier First PI generation: protease (Telaprevir & Boceprevir) High cross-resistance G1a: R155K, V36M inhibitors G1b: V36M, T54A/S, A156T ■ Second wave and second PI generation: across all but genotype 3 (D168Q) Second wave and second PI generation: (Simeprevir, faldaprevir, vaniprevir, F43S, Q80K, R155K, D168A/E/H/T/V asunaprevir, sovaprevir, MK-5172, ACH-2684) NS5 Across all genotypes High genetic barrier Sofosbuvir*: nucleos(ti)de High cross-resistance G1a: S282T+(I434M) Sofosbuvir displays less antiviral activity G1b: S282T analogues againts genotypes 3 (treatment duration 24 G2a: S282T+(T179A, M289L, I293L, inhibitors weeks of sofosbuvir+RBV).
  • Twelve-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir And

    Twelve-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir And

    bs_bs_banner doi:10.1111/jgh.14096 HEPATOLOGY Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study Jia-Horng Kao,* Min-Lung Yu,† Chi-Yi Chen,‡ Cheng-Yuan Peng,§ Ming-Yao Chen,¶ Huoling Tang,** Qiaoqiao Chen** and Jinzi J Wu** *Graduate Institute of Clinical Medicine and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, ¶Division of Gastroenterology, Department of Internal Medicine, Taipei Medical University Shuang Ho Hospital, Taipei, †Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, ‡Division of Gastroenterology, Department of Internal Medicine, Chia-Yi Christian Hospital, Chiayi, and §Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; and **Ascletis BioScience Co., Ltd., Hangzhou, China Key words Abstract danoprevir, efficacy, hepatitis C, interferon free, ravidasvir. Background and Aim: The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with Accepted for publication 9 January 2018. interferon-inclusive regimen has led to the development of new direct-acting antiviral agents. Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high Correspondence barrier to resistance. The aim of this phase 2 study (EVEREST study) was to assess the ef- Jia-Horng Kao, Graduate Institute of Clinical ficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir Medicine and Hepatitis Research Center, (DNVr) and ribavirin (RBV) regimen for treatment-naïve Asian HCV genotype 1 (GT1) National Taiwan University College of Medicine patients without cirrhosis. and Hospital, 7 Chung-Shan South Road, Taipei Methods: A total of 38 treatment-naïve, non-cirrhotic adult HCV GT1 patients were en- 10002, Taiwan.
  • Caracterización Molecular Del Perfil De Resistencias Del Virus De La

    Caracterización Molecular Del Perfil De Resistencias Del Virus De La

    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Programa de doctorado en Medicina Departamento de Medicina Facultad de Medicina Universidad Autónoma de Barcelona TESIS DOCTORAL Caracterización molecular del perfil de resistencias del virus de la hepatitis C después del fallo terapéutico a antivirales de acción directa mediante secuenciación masiva Tesis para optar al grado de doctor de Qian Chen Directores de la Tesis Dr. Josep Quer Sivila Dra. Celia Perales Viejo Dr. Josep Gregori i Font Laboratorio de Enfermedades Hepáticas - Hepatitis Víricas Vall d’Hebron Institut de Recerca (VHIR) Barcelona, 2018 ABREVIACIONES Abreviaciones ADN: Ácido desoxirribonucleico AK: Adenosina quinasa ALT: Alanina aminotransferasa ARN: Ácido ribonucleico ASV: Asunaprevir BOC: Boceprevir CCD: Charge Coupled Device CLDN1: Claudina-1 CHC: Carcinoma hepatocelular DAA: Antiviral de acción directa DC-SIGN: Dendritic cell-specific ICAM-3 grabbing non-integrin DCV: Daclatasvir DSV: Dasabuvir
  • Stamp-V3 1..249

    Stamp-V3 1..249

    23 March 2016 Volume 23 Supplement 1 S1 Volume 23 Volume Supplement 1 P ages A1–A262 ages EUROPEAN JOURNAL OF HOSPITAL PHARMACY OF HOSPITAL JOURNAL EUROPEAN ABSTRACT BOOK 21st Congress of the EAHP 16-18 March 2016 Vienna, Austria March 2016 March Contents Volume 23 Supplement 1 | EJHP March 2016 Abstracts from the EAHP 2016 Congress A1 Clinical pharmacy A172 Other hospital pharmacy topics A104 Drug distribution A178 Pharmacokinetics and pharmacodynamics A118 Drug information and pharmacotherapy A195 Production and preparation A158 General management A214 Patient safety and risk management A167 International posters A250 Author index POSTER AWARD NOMINEES Presentations on Wednesday, 16 March, 14:00–15:30, Room 93 Time Poster number Poster nominee oral presentations Author 14:00 DD-021 Medicine supply chain of a central pharmacy: risk mapping F Charra shortage 14:10 PP-001 Contamination with cytotoxic drugs in the workplace – E Korczowska ESOP pilot study 14:20 PP-039 Double checking manipulations for complex and/or high A Alcobia Martins risk preparations 14:30 CP-055 The clinical pharmacist resolves medication related E Tudela-Lopez problems in cranio, maxillofacial and oral surgery patients 14:40 CP-085 The impact of pharmacist interventions on safety M Tovar Pozo and cost savings 14:50 CP-219 Effectiveness and safety of switching to dual antiretroviral J Luis Revuelta therapy in a treatment experienced HIV cohort 15:00 DD-027 Implementation and evaluation of an appointment based F J Alvarez Manceñido model for outpatients attended in
  • Response-Guided Therapy in Patients with Genotype 1 Hepatitis C Virus: Current Status and Future Prospects Eric J Lawitz and Fernando E Membreno

    Response-Guided Therapy in Patients with Genotype 1 Hepatitis C Virus: Current Status and Future Prospects Eric J Lawitz and Fernando E Membreno

    bs_bs_banner doi:10.1111/jgh.12632 REVIEW Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects Eric J Lawitz and Fernando E Membreno The Texas Liver Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA Key words Abstract direct-acting antiviral, HCV RNA, protease inhibitors, response-guided therapy. On-treatment responses to antiviral therapy are used to determine duration of therapy in patients being treated for genotype 1 hepatitis C virus infection. Such use of response- Accepted for publication 9 March 2014. guided therapy has successfully reduced exposure of patients to the side-effects of pegylated interferon and ribavirin without jeopardizing overall treatment success. Correspondence Response-guided therapy is an integral part of treatment using the current standard treat- Dr Eric J Lawitz, 607 Camden Street, ments involving the direct-acting antiviral (DAA) agents—boceprevir or telaprevir— University of Texas Health Science Center, combined with pegylated interferon/ribavirin. Improvements in our understanding of the San Antonio, TX 78215, USA. kinetics of viral load during antiviral therapy have shown us that more potent suppression Email: [email protected] of viral replication increases the rate of viral eradication, providing impetus for the development of more potent DAAs. Emerging results from clinical trials of these agents— including trials of interferon-free DAA combinations—suggest that very high rates of viral eradication are achievable, even in patients who failed to respond to previous courses of interferon-based therapy. Furthermore, because of these high rates of treatment success, on-treatment assessment of viral response may become unnecessary.